What's Going On With Ginkgo Bioworks Stock?
What's Going On With Ginkgo Bioworks Stock?
Ginkgo Bioworks Holdings, Inc. (NASDAQ:DNA) shares are volatile Thursday. The company announced the acquisition of AgBiome's platform assets and the expansion of its strategic partnership with Novo Nordisk A/S (NYSE:NVO).
週四，銀杏生物工程控股有限公司（納斯達克股票代碼：DNA）股價波動不定。該公司宣佈收購Agbiome的平台資產，並擴大與諾和諾德A/S（紐約證券交易所代碼：NVO）的戰略合作伙伴關係。
The Details:
細節：
Ginkgo Bioworks said the assets acquired from AgBiome include over 115,000 sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata.
Ginkgo Bioworks表示，從AgBiome收購的資產包括超過11.5萬種測序和分離的菌株、超過5億個獨特的基因序列以及相關的功能數據和元數據。
"We are so excited to bring AgBiome's incredible strain and metagenomic collection into Ginkgo. This is a world class asset that will significantly expand our capabilities and can directly benefit Ginkgo's customers in the ag biologicals space. In addition to the platform assets and capabilities, the product concepts pipeline that has been validated by AgBiome to date provides an exciting opportunity to give customers a head-start in their product development efforts," said Michael Miille, Ginkgo Fellow.
“我們很高興將Agbiome令人難以置信的菌株和宏基因組集合引入銀杏樹。這是一項世界一流的資產，它將顯著擴展我們的能力，並可以直接使Ginkgo在農業生物製品領域的客戶受益。Ginkgo研究員邁克爾·米耶說，除了平台資產和功能外，迄今爲止已通過AgbiOme驗證的產品概念管道還提供了一個激動人心的機會，可以讓客戶在產品開發工作中搶佔先機。
Ginkgo Bioworks announced the expansion of its strategic partnership with Novo Nordisk A/S on Wednesday under a framework agreement that initially is contemplated to run over five years.Ginkgo said the partnership aim to improve the manufacturing of Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity medications.
Ginkgo Bioworks週三宣佈擴大與Novo Nordisk A/S的戰略合作伙伴關係，該框架協議最初計劃爲期五年。Ginkgo表示，該合作伙伴關係旨在改善諾和諾德治療嚴重慢性病（包括糖尿病和肥胖藥物）藥物的製造。
"Novo Nordisk has played an important role in shaping the landscape for pharmaceutical products in the 21st century. We're so excited to expand our partnership to help them achieve their ambitious and global goals. With this deal structure, Novo Nordisk can easily access the entire expanse of Ginkgo's pharma services from discovery through manufacturing," said Jason Kelly, Ginkgo CEO.
“諾和諾德在塑造21世紀藥品格局方面發揮了重要作用。我們很高興能夠擴大我們的合作伙伴關係，幫助他們實現雄心勃勃的全球目標。通過這種交易結構，諾和諾德可以輕鬆獲得銀杏從發現到製造的全部製藥服務。” Ginkgo首席執行官傑森·凱利說。
Related News: What's Going On With Chinese EV Stocks Nio And XPeng?
相關新聞： 中國電動汽車股票蔚來和小鵬怎麼了？
How To Buy DNA Stock:
如何購買 DNA 股票：
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了前往經紀平台購買股票的股票（或部分股票）外，您還可以通過購買本身持有股票的交易所交易基金（ETF）來獲得股票，或者將自己分配到401（k）中尋求收購共同基金或其他工具股票的策略。
For example, in Ginkgo Bioworks Holdings' case, it is in the Materials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
例如，就Ginkgo Bioworks Holdings而言，它屬於材料行業。ETF可能會持有許多有助於追蹤該行業的流動性和大型公司的股票，從而使投資者能夠了解該細分市場的趨勢。
DNA Price Action: According to Benzinga Pro, Ginkgo Bioworks shares are down 7.1% at $1.04 at the time of publication Thursday.
DNA價格走勢：根據Benzinga Pro的數據，在週四發佈時，Ginkgo Bioworks的股價下跌7.1％，至1.04美元。
Image: Markus Distelrath from Pixabay
圖片：來自 Pixabay 的 Markus Distelrath
譯文內容由第三人軟體翻譯。